Cadrenal Therapeutics, Inc. 8-K

What Happened
Cadrenal Therapeutics, Inc. filed a Current Report on Form 8‑K on May 7, 2026 (Item 2.02) announcing it issued a press release that includes financial information for the quarter ended March 31, 2026. The press release is furnished as Exhibit 99.1 to the 8‑K. The filing notifies investors that the company has reported its recent results of operations and financial condition; the 8‑K itself references the attached press release for the details.

Key Details

• Item reported: 2.02 — Results of Operations and Financial Condition (press release issued May 7, 2026).
• Period covered: Quarter ended March 31, 2026.
• Exhibit attached: Exhibit 99.1 — press release with the financial information.
• Corporate ID: Cadrenal Therapeutics, Inc. (ticker CVKD), Delaware corporation.

Why It Matters
This 8‑K signals that Cadrenal has publicly disclosed its latest quarterly results; investors should review the attached press release for revenue, profit/loss, cash position, and any management commentary or guidance. Because the 8‑K does not itself include line‑by‑line financial statements, retail investors should read the Exhibit 99.1 release and monitor subsequent SEC filings (e.g., quarterly reports) for full financial detail and context.